Philip J. Lowe

4.2k total citations
76 papers, 3.2k citations indexed

About

Philip J. Lowe is a scholar working on Molecular Biology, Oncology and Physiology. According to data from OpenAlex, Philip J. Lowe has authored 76 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 17 papers in Oncology and 17 papers in Physiology. Recurrent topics in Philip J. Lowe's work include Asthma and respiratory diseases (14 papers), Drug Transport and Resistance Mechanisms (13 papers) and Allergic Rhinitis and Sensitization (10 papers). Philip J. Lowe is often cited by papers focused on Asthma and respiratory diseases (14 papers), Drug Transport and Resistance Mechanisms (13 papers) and Allergic Rhinitis and Sensitization (10 papers). Philip J. Lowe collaborates with scholars based in Switzerland, United Kingdom and United States. Philip J. Lowe's co-authors include R. Coleman, S.G. Barnwell, Stacey Tannenbaum, Guy Meno‐Tetang, Didier Renard, David Floch, Christiane Rordorf, William M. Sallas, Yuko Tsukamoto and David C. Billington and has published in prestigious journals such as The Journal of Experimental Medicine, Hepatology and Biochemical Journal.

In The Last Decade

Philip J. Lowe

75 papers receiving 3.1k citations

Peers

Countries citing papers authored by Philip J. Lowe

Since Specialization

Citations

This map shows the geographic impact of Philip J. Lowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Lowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Lowe more than expected).

Fields of papers citing papers by Philip J. Lowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Lowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Lowe. The network helps show where Philip J. Lowe may publish in the future.

Co-authorship network of co-authors of Philip J. Lowe

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Lowe. A scholar is included among the top collaborators of Philip J. Lowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Lowe. Philip J. Lowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effect of frozen embryo transfer regimen on the association between serum progesterone and live birth: a multicentre prospective cohort study (ProFET) 2022 ·Human Reproduction Open ·Pedro Melo, Simon Wood, (unknown), (unknown), Christina Easter, Malcolm J Price, Simon Fishel, Mohammed Khairy, Charles Kingsland, Philip J. Lowe, Madhurima Rajkhowa, (unknown), Shilpi Pandey, (unknown), David Walker, (unknown), (unknown), Ioannis Gallos, Amanda Tozer, Arri Coomarasamy	12
2	Serum luteal phase progesterone in women undergoing frozen embryo transfer in assisted conception: a systematic review and meta-analysis 2021 ·Fertility and Sterility ·Pedro Melo, (unknown), (unknown), Malcolm J Price, Simon Fishel, Mohammed Khairy, Charles Kingsland, Philip J. Lowe, (unknown), Madhurima Rajkhowa, (unknown), Amanda Tozer, Simon Wood, Elena Labarta, (unknown), Adam Devall, Ioannis Gallos, Arri Coomarasamy	73
3	Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion 2015 ·Drug Metabolism and Pharmacokinetics ·(unknown), (unknown), (unknown), Masayuki Yamaguchi, Philip J. Lowe	16
4	Multicentre study of the clinical relevance of screening IVF patients for carrier status of the annexin A5 M2 haplotype 2014 ·Reproductive BioMedicine Online ·Simon Fishel, (unknown), (unknown), (unknown), (unknown), Paula Smith, Craig E. Cameron, Simon Thornton, Ken Dowell, Glenn Atkinson, (unknown), Philip J. Lowe, (unknown), (unknown), (unknown)	7
5	Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies 2014 ·The AAPS Journal ·Mohamed Elmeliegy, Philip J. Lowe, Wojciech Krzyżański	9
6	QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects 2013 ·European Respiratory Journal ·(unknown), (unknown), Andrej Skerjanec, (unknown), Philip J. Lowe, Suzanne Maahs	3
7	Population Pharmacokinetic and Pharmacodynamic Model‐Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575 2011 ·The Journal of Clinical Pharmacology ·Xiaoyu Yan, Philip J. Lowe, Martin Fink, (unknown), Sigrid Balser, Wojciech Krzyżański	31
8	Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations 2010 ·The Journal of Clinical Pharmacology ·Wojciech Krzyżański, Paweł Wiczling, Philip J. Lowe, Etienne Pigeolet, Martin Fink, (unknown), Sigrid Balser	36
9	Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development 2010 ·Clinical Pharmacology & Therapeutics ·Philip J. Lowe	10
10	Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma 2009 ·British Journal of Clinical Pharmacology ·Philip J. Lowe, Stacey Tannenbaum, (unknown), Pablo A. Jimenez	124
11	Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations 2009 ·Clinical Pharmacokinetics ·Paweł Wiczling, Philip J. Lowe, Etienne Pigeolet, Frank Lüdicke, Sigrid Balser, Wojciech Krzyżański	20
12	Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885): results from a subcutaneous administration study 2008 ·UCL Discovery (University College London) ·Helen J. Lachmann, Thomas Jung, (unknown), Philip J. Lowe, Mark Offer, (unknown), Philip N. Hawkins	4
13	Exploring the Effect on Asthma Control of Omalizumab Reduction After 28 Weeks Treatment 2007 ·Journal of Allergy and Clinical Immunology ·Raymond G. Slavin, Philip J. Lowe, (unknown), H. Fox, (unknown), Cristina Martín, William M. Sallas	2
14	A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab 2006 ·British Journal of Clinical Pharmacology ·(unknown), Yuko Tsukamoto, William M. Sallas, Philip J. Lowe	141
15	Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia 2005 ·Australian and New Zealand Journal of Obstetrics and Gynaecology ·Philip J. Lowe, Gab Kovacs, (unknown)	32
16	Outcome of pregnancies achieved by in vitro fertilisation techniques and diagnosed as twins at the 6 week ultrasound 2004 ·Australian and New Zealand Journal of Obstetrics and Gynaecology ·(unknown), Sue Breheny, Vivien MacLachlan, Philip J. Lowe, (unknown)	4
17	Evaluation of serum inhibin A as a surveillance marker after conservative management of tubal pregnancy 1998 ·Human Reproduction ·Donato D’Antona, Pam Mamers, Philip J. Lowe, N.D.H. Balazs, N. P. Groome, Euan M. Wallace	8
18	A Casemix Cost Comparison of 2 Treatments For Ectopic Pregnancy 1998 ·Australian and New Zealand Journal of Obstetrics and Gynaecology ·Philip J. Lowe, Pamela Mamers, (unknown), David Healy	5
19	Different influence of incongruent follicular development on in vitro fertilization–embryo transfer and gamete intrafallopian transfer pregnancy rates 1998 ·Fertility and Sterility ·Talia Eldar‐Geva, Philip J. Lowe, Vivien MacLachlan, Luk Rombauts, David Healy	4
20	BREAKDOWN OF HEPATIC TIGHT JUNCTIONS DURING REOXYGENATION INJURY 1992 ·Transplantation ·Hiroyuki Konno, Philip J. Lowe, W.G.M. Hardison, Katsumi Miyai, Satoshi Nakamura, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact